Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 1, 2004, Pages 21-24

  Afshar Kharghan, Vahid ^a   López, José A ^a   Gray, Leigh A ^b   Padilla, Arnoldo ^a   Borthakur, Gautam ^c   Roberts, Stacy C ^c   Pruthi, Rajiv K ^b   Tefferi, Ayalew ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Essential thrombocythemla; Factor II; Factor V; Platelet glycoprotein; Polycythemia vera

Indexed keywords

ALANINE; ALPHA2 INTEGRIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; GLYCINE; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IIIA; PROTHROMBIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTHEMIA; VASOMOTOR DISORDER; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CORONARY THROMBOSIS; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROTHROMBIN; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 2042477375     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200401000-00004     Document Type: Article

References (24)

1. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1-12.
2. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001; 15:121-131.
3. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003; 78:174-194.
4. Raskind WH, Steinmann L, Najfeld V. Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia 1998; 12:108-116.
5. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 1978; 299:505-509.
6. Wu KK. Platelet hyperaggregability and thombosis in patients with thrombocythemia. Ann Intern Med 1978; 88:7-11.
7. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95:82-86.
8. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36(suppl 2):9-13.
9. López JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Ibα results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region: structure/function implications. J Biol Chem 1992; 267:10055-10061.
10. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PIA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol 1995; 89:169-176.
11. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, López JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood 1999; 94:186-191.
12. 1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93:3578-3582.
13. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999; 81:733-738.
14. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients. Ann Hematol 1991; 63:101-106.
15. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94:1063-1069.
16. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000; 7:284-289.
17. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334:1090-1094.
18. A polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 2000; 36:84-89.
19. Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96:3281-3286.
20. Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet glycoprotein Ibα HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001; 104:876-880.
21. Cadroy Y, Sakariassen KS, Charlet JP, Thalamas C, Boneu B, Sie P. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 2001; 98:3159-3161.
22. Meisel C, Afshar-Kharghan V, Cascorbi I, Laule M, Stangl V, Felix SB, et al. Role of Kozak sequence polymorphism of platelet glycoprotein Ibα as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol 2001; 38:1023-1027.
23. 2 gene in platelet GP Ia collagen receptor expression and function - effect in thromboembolic diseases. Thromb Haemost 1999; 81:951-956.
24. 1 density. Blood 1998; 92:2382-2388.